Riociquat, an sGC stimulator, has shown efficacy as a vasodilator in a phase III trial for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension18 and as a treatment for portal hypertension. The gene discussed is SGCB; the disease is portal hypertension.